Immuneering Corp cotiza a 3.86 USD y tiene una capitalización bursátil de $250M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung ca…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.27 | $-0.21 | $-0.18 |
| Estimado | $-0.31 | $-0.27 | $-0.25 | $-0.31 |
| Sorpresa | — | +0.0% | +16.0% | +41.9% |
| Métrica | IMRX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -25.6% | -40.4% | +14.8% |
| ROA | -24.1% | -32.0% | +7.9% |
| Current Ratio | 17.50 | 2.84 | +14.66 |
| Debt / Equity | — | 0.28 | — |